Sarepta Therapeutics (NASDAQ:SRPT) Upgraded at StockNews.com

StockNews.com upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a hold rating to a buy rating in a report issued on Tuesday.

Other research analysts have also issued research reports about the company. Jefferies Financial Group initiated coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 target price for the company. Barclays dropped their target price on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Raymond James restated an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Finally, Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. One investment analyst has rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Buy” and an average price target of $181.33.

Sarepta Therapeutics Stock Down 3.0 %

Shares of NASDAQ:SRPT opened at $109.11 on Tuesday. Sarepta Therapeutics has a 1 year low of $78.67 and a 1 year high of $173.25. The business has a 50 day simple moving average of $124.21 and a two-hundred day simple moving average of $132.49. The firm has a market capitalization of $10.42 billion, a PE ratio of 87.29 and a beta of 0.81. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Insider Transactions at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 14.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of large investors have recently made changes to their positions in SRPT. Innealta Capital LLC purchased a new stake in shares of Sarepta Therapeutics during the second quarter valued at $31,000. New Covenant Trust Company N.A. purchased a new stake in shares of Sarepta Therapeutics during the first quarter valued at $32,000. Huntington National Bank grew its holdings in shares of Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 175 shares during the last quarter. Nkcfo LLC purchased a new stake in shares of Sarepta Therapeutics during the second quarter valued at $43,000. Finally, Riggs Asset Managment Co. Inc. grew its holdings in shares of Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 75 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.